.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01X_OtherAntibacterials.J01XX08_Linezolid.Linezolid_1 .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01X_OtherAntibacterials.J01XX08_Linezolid.Linezolid_1| name: | Linezolid_1 |
| ATC code: | J01XX08_1 | route: | intravenous |
| n-compartments | 2 |
Linezolid is a synthetic antibiotic of the oxazolidinone class. It is primarily used to treat infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Linezolid is approved for clinical use and commonly prescribed for pneumonia, skin and soft tissue infections, and other severe bacterial infections.
Pharmacokinetic parameters in healthy adult volunteers aged 18-55 years after single IV 600 mg dose, both sexes.
Heidari, S, & Khalili, H (2023). Linezolid pharmacokinetics: a systematic review for the best clinical practice. European journal of clinical pharmacology 79(2) 195–206. DOI:10.1007/s00228-022-03446-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36565357
Thibault, C, et al., & Autmizguine, J (2019). Population Pharmacokinetics of Intravenous Linezolid in Premature Infants. The Pediatric infectious disease journal 38(1) 82–88. DOI:10.1097/INF.0000000000002067 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29634620
Sakurai, N, et al., & Kakeya, H (2022). Population pharmacokinetics of linezolid and its major metabolites PNU-142300 and PNU-142586 in adult patients. Pharmacotherapy 42(9) 707–715. DOI:10.1002/phar.2719 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35856168